These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25786586)

  • 1. Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases.
    Bal K; Kałuzińska-Parzyszek I; Sobocińska A; Podlecka D; Jerzyńska J; Stelmach I
    Indian J Pediatr; 2015 Aug; 82(8):768-9. PubMed ID: 25786586
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
    Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
    Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
    [No Abstract]   [Full Text] [Related]  

  • 4. New choices for treatment with subcutaneous immunoglobulins.
    Pleguezuelo DE; Sánchez-Ramón S
    Med Clin (Barc); 2017 Jan; 148(2):86-90. PubMed ID: 27919413
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
    Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S
    Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunoglobulins and immune deficiency: methods of administration].
    Suarez F
    Rev Med Interne; 2005 Oct; 26 Spec No 1():25-8. PubMed ID: 16475260
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
    Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
    J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
    Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
    J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
    Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
    J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous Immunoglobulin in Oncology Clinical Practice.
    Streu E
    Clin J Oncol Nurs; 2016 Aug; 20(4):437-9. PubMed ID: 27441518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.
    Borte M; Quinti I; Soresina A; Fernández-Cruz E; Ritchie B; Schmidt DS; McCusker C
    J Clin Immunol; 2011 Dec; 31(6):952-61. PubMed ID: 21932110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study.
    Hachulla E; Le Masson G; Solé G; Hamidou M; Desnuelle C; Azulay JP; Besson G; Swiader L; Abad S; Antoine JC; Bouhour F; Créange A; Grenouillet M; Magy L; Marcel S; Paquet JM; Rouhart F; Ziegler F; Mathis S; Gauthier-Darnis M; Puget S
    Biomed Res Int; 2018; 2018():8147251. PubMed ID: 29736397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nursing guidelines for administration of immunoglobulin replacement therapy.
    Younger ME; Aro L; Blouin W; Duff C; Epland KB; Murphy E; Sedlak D;
    J Infus Nurs; 2013; 36(1):58-68. PubMed ID: 23271153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
    Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
    Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.